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Abstract
Deletion of TIEG1/KLF10 in mice results in a gender specific osteopenic skeletal phenotype with significant defects in both
cortical and trabecular bone, which are observed only in female animals. Calvarial osteoblasts isolated from TIEG1 knockout
(KO) mice display reduced expression levels of multiple bone related genes, including Runx2, and exhibit significant delays
in their mineralization rates relative to wildtype controls. These data suggest that TIEG1 plays an important role in
regulating Runx2 expression in bone and that decreased Runx2 expression in TIEG1 KO mice is in part responsible for the
observed osteopenic phenotype. In this manuscript, data is presented demonstrating that over-expression of TIEG1 results
in increased expression of Runx2 while repression of TIEG1 results in suppression of Runx2. Transient transfection and
chromatin immunoprecipitation assays reveal that TIEG1 directly binds to and activates the Runx2 promoter. The zinc finger
containing domain of TIEG1 is necessary for this regulation supporting that activation occurs through direct DNA binding. A
role for the ubiquitin/proteasome pathway in fine tuning the regulation of Runx2 expression by TIEG1 is also implicated in
this study. Additionally, the regulation of Runx2 expression by cytokines such as TGFb1 and BMP2 is shown to be inhibited
in the absence of TIEG1. Co-immunoprecipitation and co-localization assays indicate that TIEG1 protein associates with
Runx2 protein resulting in co-activation of Runx2 transcriptional activity. Lastly, Runx2 adenoviral infection of TIEG1 KO
calvarial osteoblasts leads to increased expression of Runx2 and enhancement of their ability to differentiate and mineralize
in culture. Taken together, these data implicate an important role for TIEG1 in regulating the expression and activity of
Runx2 in osteoblasts and suggest that decreased expression of Runx2 in TIEG1 KO mice contributes to the observed
osteopenic bone phenotype.
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Introduction
The TGFb inducible early gene-1 (TIEG1), also known as
KLF10, is a member of the Kru ¨ppel family of transcription factors
which was originally identified as a primary response gene
following TGFb1 treatment of human osteoblasts [1]. Expression
of TIEG1 is also rapidly induced by estrogen [2], BMPs [3], and
EGF [1]. TIEG1 encodes a 480 amino acid protein which
contains several Src homology domains in its N-terminal region
and three C2H2 type zinc finger DNA binding domains in its C-
terminal region [4]. Previously, we demonstrated that TIEG1
potentiates TGFb1/Smad signaling through repression of the
inhibitory Smad7 gene and activation of the Smad2 gene [5,6].
Over-expression of TIEG1 mimics the effects of TGFb1i na
number of cell types including osteoblasts [7] and pancreatic
carcinoma cells [8]. Expression of TIEG1 in cancer cells is known
to inhibit cell proliferation [7] and induce apoptosis [8,9].
Moreover, TIEG1 levels inversely correlate with the progression
and stages of breast cancer [10].
In addition to the inhibition of cell proliferation and induction
of apoptosis, many other biological functions of TIEG1 have been
identified through the development and characterization of
knockout (KO) mice [11] including essential roles for this gene
in normal heart [12], tendon [13,14] and immune system [15,16]
function. Our laboratory has also verified a role for TIEG1 in
regulating skeletal development and maintenance. TIEG1 KO
mice exhibit a gender-specific osteopenic phenotype characterized
by decreased bone mineral density, bone mineral content and
overall loss of bone strength only in female animals [17,18]. At the
cellular level, calvarial osteoblasts isolated from KO mice exhibit
delayed rates of differentiation and defects in matrix production
and mineralization [11]. Female TIEG1 KO mice also exhibit
reduced osteocyte numbers with alterations in their ultra-structure
[19]. Finally, we have demonstrated a reduction in the ability of
TIEG1 KO osteoblasts to support osteoclast differentiation in vitro
[11]. At the molecular level, loss of TIEG1 alters the expression of
bone matrix genes as well as important osteoblast regulatory genes
[11]. The expression of receptor activator of NFkB (RANKL), an
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osteoblasts while the levels of osteoprotegerin (OPG), an inhibitor
of osteoclastogenesis, are increased [11,20]. These changes in
expression of RANKL and OPG partially explain the loss of
osteoblast support of osteoclastogenesis in these KO mice. As an
extension of these studies, we have recently demonstrated that
TIEG1 directly binds to GC-rich elements in the OPG promoter
to suppress gene transcription [21]. However, the regulation of
RANKL expression by TIEG1 appears to be indirect as no
alterations in the activity of the RANKL promoter were observed
in the presence or absence of TIEG1 expression [21].
Runx2 is known to be an important regulator of cell phenotype
commitment and growth [22–26] and is considered a master gene
in bone as it is essential for osteoblast lineage commitment,
differentiation, bone matrix formation and mineralization [27–
29]. Ablated or defective Runx2 expression in mice is lethal as
there is an absence of osteoblasts and bone in such animal models
[27,30,31]. Runx2 also plays a key role in mediating the BMP and
TGFb pathways which are important for osteoblast development
and growth [32,33]. Runx2 is required for normal expression of
many genes known to be markers of a mature osteoblast including
osteocalcin, type 1 collagen, ERa, Vit D receptor, alkaline
phosphatase, bone sialo-protein, osteoprotegerin, osteopontin,
collagenase, MCSF, BCL-2, RANKL, and osterix [34–42,29].
As expected, tight regulation of Runx2 expression is necessary to
ensure normal bone formation and maintenance as mice which
over-express Runx2 specifically in osteoblasts also exhibit an
osteopenic bone phenotype [43,40]. Due to the importance of
Runx2 in bone, identification of specific proteins that regulate
Runx2 expression and function is essential to further our
understanding of bone biology. Such genes and their associated
pathways could serve as novel therapeutic targets for the treatment
of numerous bone disorders including osteoporosis and fracture
repair among others.
Based on the observed osteopenic phenotype of TIEG1 KO
mice and the importance of Runx2 in bone, we sought to
determine if alterations in Runx2 expression and/or function were
observed in the absence of TIEG1. This study demonstrates that
TIEG1 not only directly regulates Runx2 expression in osteoblasts,
but also plays an active role in mediating Runx2 responses
following TGFb1 and BMP2 treatment. Additionally, the results
indicate that TIEG1 associates with Runx2 protein and functions
as a co-activator of Runx2 transcriptional activity. Further,
decreased Runx2 expression in TIEG1 KO osteoblasts is at least
in part responsible for their observed defects in differentiation and
mineralization. Taken together, these data identify TIEG1 as a
novel modulator of Runx2 expression and function and further
implicate its importance in normal bone development and
maintenance.
Results
Runx2 Expression in TIEG1 KO Osteoblasts
This laboratory has previously demonstrated that calvarial
osteoblasts isolated from TIEG1 KO mice exhibit reduced
mineralization rates and decreased expression of a number of
osteoblast marker genes relative to wildtype controls [11]. Due
to the crucial role of Runx2 in mediating osteoblast
differentiation and mineralization [27–29], it was of interest
to quantify the expression levels of this gene in TIEG1 KO
cells. Runx2 expression levels were analyzed in calvarial
osteoblasts isolated from three individual wildtype and KO
neonates via real-time RT-PCR. As shown in Figure 1A,
Runx2 expression levels were significantly reduced in KO
osteoblasts relative to wildtype littermates. Consistent with
mRNA levels, nuclear Runx2 protein levels were also
significantly repressed in KO cells as determined by quanti-
tative confocal microscopy (Figure 1 B and C). These data
suggest a role for TIEG1 in regulating the expression levels of
this important osteogenic gene.
Suppression of TIEG1 results in decreased Runx2 levels
Since our TIEG1 mouse model is a global KO, we sought to
determine if the effect of loss of TIEG1 expression on Runx2 levels
was cell autonomous in osteoblasts. Wildtype calvarial osteoblasts
were transfected with either non-sense (scrambled TIEG1 siRNA
sequence), GAPDH or TIEG1 specific siRNA duplexes and the
expression levels of TIEG1 and Runx2 were determined by real-
time RT-PCR following normalization to untransfected control
cells. TIEG1 expression was decreased by approximately 80% in
cells transfected with the TIEG1 specific siRNA, but was unaltered
in cells transfected with scrambled TIEG1 or GAPDH specific
siRNAs (Figure 2A). Runx2 expression was also decreased by
approximately 80% in cells transfected with TIEG1 siRNA, but
not in cells transfected with non-sense or GAPDH siRNAs
(Figure 2B). Since suppression of TIEG1 resulted in significant
decreases in Runx2 expression, we next determined if this was
associated with decreased expression of other osteoblast-related
and Runx2 target genes. Indeed, the expression levels of
osteocalcin, osteopontin, osterix and bone sialoprotein were also
decreased in WT calvarial osteoblasts following transfection with a
TIEG1 specific siRNA (Figure 2C). These studies provide further
evidence that decreased expression of TIEG1 results in suppres-
sion of Runx2 and implicate TIEG1 as a novel regulator of Runx2
in osteoblasts. Furthermore, these studies provide evidence that
decreased TIEG1 levels are also associated with decreased
expression of other osteoblast-related genes, either as a result of
direct regulation by TIEG1 or due to decreased expression of
Runx2.
Over-expression of TIEG1 results in increased Runx2
levels
As a complement to the siRNA studies, Runx2 expression levels
were also determined in two different cell model systems in which
TIEG1 was over-expressed. First, TIEG1 expression was activated
in a U2OS-doxycycline inducible cell line (Tet-TIEG1) which was
developed in our laboratory. TIEG1 expression was significantly
elevated within 8 hours of doxycycline treatment, peaked at
approximately 12 hours and was maintained at high levels at the
24 hour time point (Figure 3A). Subsequent to the induction of
TIEG1 expression, Runx2 expression levels peaked at the 12 hour
time point and remained elevated at 24 hours (Figure 3A).
We next determined if restoration of TIEG1 expression in
calvarial osteoblasts isolated from TIEG1 KO mice would result in
increased Runx2 expression levels. Infection of KO cells with a
TIEG1 adenovirus resulted in an approximately 3.5 fold increase
in TIEG1 expression levels (Figure 3B). As expected, Runx2
expression levels were also significantly elevated following
induction of TIEG1 (Figure 3B). As a complement to the data
shown in Figure 2C, we next determined if increased expression of
TIEG1 and Runx2 were also associated with elevated levels of
other osteoblast-related genes. As shown in Figure 3C, infection of
KO calvarial osteoblasts with a TIEG1 adenovirus led to
significant up-regulation of osteocalcin, osteopontin, osterix and
bone sialoprotein expression. Taken together, these data reveal
that increased expression of TIEG1 leads to induction of Runx2
and other osteoblast-related genes.
TIEG1 Regulation of Runx2 Expression and Activity
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19429Figure 1. Runx2 expression levels are decreased in osteoblasts isolated from TIEG1 KO mice relative to WT controls. Calvarial
osteoblasts were isolated from three wild-type (WT) and three TIEG1 knockout (KO) neonatal pups and cultured in vitro.( A) Total RNA was isolated
from proliferating cells and real-time PCR analysis was performed to measure Runx2 mRNA levels. The results are depicted as relative expression
levels compared to WT cells and represent average Runx2 expression across three distinct cell lines. (B) Representative confocal microscopy image
depicting TIEG1 and Runx2 protein levels in WT and TIEG1 KO calvarial osteoblasts. (C) Quantitation of TIEG1 and Runx2 protein levels in WT and
TIEG1 KO calvarial osteoblasts. Asterisks denote significance at the p,0.05 level (ANOVA) compared with WT cells.
doi:10.1371/journal.pone.0019429.g001
TIEG1 Regulation of Runx2 Expression and Activity
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19429TIEG1 mediates Runx2 responsiveness following TGFb1
and BMP2 stimulation
Since Runx2 expression is known to be induced within
2 hours by both TGFb1 and BMP2 [32], and since TIEG1
expression is also rapidly induced by these two growth factors
within 1 hour [44,3], we next sought to determine if TIEG1
plays a role in mediating the induction of Runx2 by these two
important bone anabolic cytokines. In order to monitor
alterations in Runx2 expression in response to these cytokines
as a result of TIEG1, three wild-type and three TIEG1 KO
calvarial osteoblast cell lines were exposed to TGFb1o rB M P 2
for 2 hours and Runx2 expression levels were monitored by real-
time PCR. As expected, Runx2 expression was rapidly induced
by both TGFb1 and BMP2 in wildtype cells (Figure 4A).
However, this induction was nearly abolished in TIEG1 KO
cells (Figure 4A) suggesting that TIEG1 plays a role in mediating
the response of Runx2 expression in osteoblasts following
TGFb1 and BMP2 stimulation.
Figure 2. Suppression of TIEG1 in osteoblasts results in decreased expression of Runx2 and other osteoblast-related genes. Calvarial
osteoblasts isolated from three wild-type neonatal pups were transfected with indicated siRNA constructs for 48 hours. Total RNA was isolated and
TIEG1 (A) and Runx2 (B) expression levels were determined using real-time PCR. Data is reported as relative expression levels compared to
untransfected cells. (C) The expression levels of osteocalcin (OC), osteopontin (OP), osterix (OSX) and bone sialoprotein (BSP) were also determined in
WT calvarial osteoblasts transfected with the TIEG1 specific siRNA relative to cells transfected with the scrambled siRNA. Asterisks denote significance
at the p,0.05 level (ANOVA) compared with indicated controls.
doi:10.1371/journal.pone.0019429.g002
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restoration of TIEG1 expression in KO calvarial osteoblasts
restored the ability of TGFb1 and BMP2 to induce Runx2
expression. As expected, over-expression of TIEG1 in KO cells led
to increased expression of Runx2, however, no further increases in
Runx2 expression levels were observed in response to TGFb1o r
BMP2 treatment (data not shown). This observation suggested that
the induction of TIEG1 expression by TGFb1 and BMP2 was an
essential component in the cascade of events leading to up-
regulation of Runx2 by these two cytokines. In order to address
this possibility, we next suppressed TIEG1 expression in WT
calvarial osteoblasts using a TIEG1 specific siRNA and subse-
quently monitored Runx2 expression levels following 2 hours of
TGFb1 or BMP2 treatment. Interestingly, suppression of TIEG1
prevented the induction of Runx2 expression following TGFb1
and BMP2 treatment (Figure 4B). However, these two cytokines
induced Runx2 expression in WT cells transfected with a
scrambled (NT) siRNA (Figure 4B). Taken together, these data
suggest that increased expression of TIEG1 following TGFb1 and
BMP2 stimulation is necessary for the rapid induction of Runx2
expression by these two cytokines in osteoblast cells.
TIEG1 activates the Runx2 promoter
Since the above data support a role for TIEG1 in regulating
Runx2 expression, we next determined if TIEG1 could activate
the Runx2 promoter. As a first step, an approximately 600 base
pair fragment of the Runx2 P1 promoter [45] was analyzed for
potential TIEG1 binding sites using the Genomatix software suite
(Munich, Germany). This transcription factor binding site search
identified multiple putative kru ¨ppel-like transcription factor
binding sites which are indicated in Figure 5A. This promoter
construct was subsequently transfected into U2OS cells with a
control expression vector, a full-length TIEG1 expression vector or
a truncated TIEG1 expression vector in which the DNA binding
domain was deleted (TIEG1 1–370) to determine if TIEG1 could
regulate its activity. As shown in Figure 5B, intact TIEG1
Figure 3. Over-expression of TIEG1 in osteoblasts results in increased expression of Runx2 and other osteoblast-related genes. (A)
Inducible U2OS-TIEG1 cells (U2OS Tet-TIEG1) were treated with doxycycline for indicated times. Total RNA was harvested and TIEG1 and Runx2
expression levels were monitored by real-time PCR. (B–C) Calvarial osteoblasts isolated from three TIEG1 knockout (KO) neonatal pups were infected
with either control or TIEG1 adenovirus for 24 hours. Total RNA was isolated and TIEG1 and Runx2 expression levels (B), as well as osteocalcin (OC),
osteopontin (OP), osterix (OSX) and bone sialoprotein (BSP) (C), were determined using real-time PCR. The results are expressed as relative fold
change compared to no doxycycline treatment (A) or to control adenoviral infected cells (B–C). Asterisks denote significance at the p,0.05 level
(ANOVA) compared with controls.
doi:10.1371/journal.pone.0019429.g003
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TIEG1 was shown to be essential for this activation since deletion
of the zinc-finger containing domain rendered this protein inactive
on the Runx2 promoter (Figure 5B). To further define the region
of the Runx2 promoter through which TIEG1 functions, 59-
deletion constructs of the promoter [45] were transfected into
U2OS cells with either a control or full-length TIEG1 expression
vector. All of the promoter constructs analyzed were significantly
induced by TIEG1, and the levels of induction progressively
increased as the 59-region of the Runx2 promoter was deleted
(Figure 5C). Since the 292 bp fragment of the Runx2 promoter
appeared to be the most active, this region was then deleted in the
context of the full-length promoter. Deletion of this 39-region did
not completely abolish the TIEG1 induction of promoter activity,
and in fact, the activity of this construct was nearly identical to that
of the intact 2600 bp promoter (Figure 5C). These data indicate
that TIEG1 likely utilizes multiple binding sites located throughout
the Runx2 promoter and furthermore suggest that repressive
domains, which reduce the ability of TIEG1 to activate this
promoter, are contained within the distal regions of the Runx2 P1
promoter.
TIEG1 stabilization further enhances Runx2 promoter
activity
Our laboratory has previously reported that TIEG1 expression
and function is tightly regulated by the ubiquitin/proteasome
system as TIEG1 protein is a direct target for the E3 ubiquitin
ligase, seven in absentia homolog 1 (SIAH1) [46]. The SIAH1
binding site for TIEG1 has been mapped [47] and mutation of
valine 205 and proline 207 to asparagines (TIEG1-NxN) results in
stabilization of this protein. Based on these previous observations,
we examined whether this pathway may be involved in
modulating Runx2 expression as a result of TIEG1 stability. As
expected, increased expression of SIAH1 in U2OS cells com-
pletely abolished TIEG1 protein levels (Figure 6A). However, co-
transfection of the TIEG1-NxN expression construct resulted in
significant stabilization of this protein in the presence of SIAH1
(Figure 6A). Stabilization of TIEG1 protein levels (TIEG1-NxN)
resulted in further activation of the 2600 Runx2 promoter
construct relative to WT TIEG1 (Figure 6B). While these data do
not directly implicate a role for SIAH1 in modulating Runx2
expression via TIEG1 stability, they do suggest that the ubiquitin/
proteasome pathway may be involved in fine tuning the expression
levels of Runx2 in osteoblasts through mediating TIEG1 protein
levels.
TIEG1 directly binds to the Runx2 promoter
Based on the previous data indicating a role for TIEG1 in
regulating Runx2 expression, we next sought to determine if
TIEG1 protein directly binds to the Runx2 promoter. As a first
step, the Runx2 2600 promoter construct was co-transfected into
U2OS cells with either a control, full-length TIEG1 or truncated
TIEG1 (TIEG1 1–370) expression vector. Chromatin immuno-
precipitation (ChIP) assays revealed increased binding of full-
length TIEG1, but not truncated TIEG1 (TIEG1 1–370), above
control levels (Figure 7A and B) demonstrating that TIEG1 does
associate with the Runx2 promoter in a DNA binding dependent
manner. TIEG1 binding was further enhanced on the Runx2
2288 and 292 promoter constructs relative to the full-length
promoter construct with maximal levels of binding observed on
the Runx2 2288 promoter fragment (Figure 7C and D). These
data correlate well with the potential TIEG1 binding sites
indentified in the Runx2 promoter as shown in Figure 5A since
10 of the 13 putative TIEG1 binding sites are contained within the
Figure 4. TIEG1 mediates Runx2 expression in osteoblasts
following TGFb1 and BMP2 stimulation. (A) Calvarial osteoblasts
isolated from three wild-type (WT) and three TIEG1 knockout (KO)
neonatal pups were treated with vehicle, TGFb1 or BMP2 for 2 hours.
Total RNA was isolated and Runx2 expression levels were monitored by
real-time PCR. The results are expressed as relative fold change
compared to vehicle treated cells and represent average Runx2
expression across three distinct cell lines. (B) WT calvarial osteoblasts
were transfected with a scrambled (NT) or TIEG1 specific siRNA for
24 hours and subsequently treated with vehicle, TGFb1 or BMP2 for
2 hours. Total RNA was isolated and Runx2 expression levels were
determined by real-time PCR relative to vehicle controls. Asterisks
denote significance at the p,0.05 level (ANOVA) compared to vehicle
controls. d denotes significance at the p,0.05 level (ANOVA) between
WT and KO cells (A) or between WT cells transfected with either a
scrambled (NT) or TIEG1 specific siRNA (B).
doi:10.1371/journal.pone.0019429.g004
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the 292 bp fragment was the most highly activated construct by
TIEG1 at the transcriptional level (Figure 5C) suggesting that
repression domains are located between 2288 and 292 bps which
inhibit optimal activation of the Runx2 promoter by TIEG1. The
basis for decreased binding of TIEG1 to the 2600 bp construct is
also likely explained by the presence of inhibitory factors/
repressive domains located in the distal regions of the Runx2
promoter that block TIEG1’s ability to bind to and/or optimally
activate this promoter fragment. Nevertheless, these data reveal
Figure 5. Regulation of Runx2 promoter activity by TIEG1 in osteoblasts. (A) Putative kru ¨ppel-like transcription factor binding sites located
within the 2600 bp fragment of the Runx2 P1 promoter as identified using the Genomatix software suite. Kru ¨ppel-like transcription factor (KLTF),
mouse kru ¨ppel like factor (MKLF), kru ¨ppel like zinc finger (KLZF) and C2H2 zinc finger containing transcription factor (C2H2) binding sites are
indicated. (B) U2OS cells were transiently transfected with indicated control, full-length TIEG1 (1–480) or truncated TIEG1 (1–370) expression vectors
and the full-length Runx2 promoter (2600) fused to a luciferase reporter. (C) U2OS cells were transiently transfected with indicated control or Runx2
promoter constructs fused to a luciferase reporter along with the full-length (1–480) TIEG1 expression construct. Twenty four hours post-transfection,
luciferase activity was monitored and values are reported as relative fold change compared to controls following normalization to total protein levels.
Asterisks denote significance at the p,0.05 level (ANOVA) compared with control values. d denotes significance at the p,0.05 level (ANOVA)
between indicated promoter constructs.
doi:10.1371/journal.pone.0019429.g005
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DNA binding dependent manner and further confirm a role for
TIEG1 in regulating Runx2 expression.
TIEG1 interacts with Runx2 protein and regulates its
activity
Since TIEG1 and Runx2 are both transcription factors which
are known to regulate multiple bone related genes, and since we
have demonstrated that TIEG1 directly regulates Runx2 expres-
sion, we next examined whether TIEG1 could interact with the
Runx2 protein and mediate its activity. U2OS cells were first co-
transfected with TIEG1 and Runx2 expression constructs for
24 hours. Cell lysates were immunoprecipitated with normal
rabbit IgG, a Runx2 specific antibody or a TIEG1 specific
antibody followed by western blotting with reciprocal antibodies.
As shown in Figure 8A, TIEG1 protein was immunoprecipitated
with the Runx2 specific antibody, and Runx2 protein was
immunoprecipitated with the TIEG1 specific antibody. Neither
protein was immunoprecipitated with the non-specific IgG control
antibody (Figure 8A). These data demonstrate that these two
proteins specifically associate with each other in a protein
complex. Furthermore, TIEG1 and Runx2 protein were shown
to co-localize in the nucleus of WT calvarial osteoblasts via
confocal microscopy providing further support for the interaction
of these two transcription factors in osteoblasts (Figure 8B). In
order to determine if this interaction affected Runx2 transcrip-
tional activity, U2OS cells were next transfected with a known
Runx2-responsive luciferase reporter construct, p6OSE2-Luc
[48], and either a TIEG1 or Runx2 expression construct, alone
or in combination. As expected, Runx2 induced p6OSE2 activity;
however TIEG1 alone had no effect on this enhancer element
(Figure 8C). Importantly, co-expression of TIEG1 and Runx2 led
to co-activation of this reporter construct (Figure 8C). In
combination, these data demonstrate that TIEG1 and Runx2
proteins are able to associate with one another in a complex
leading to increased Runx2 transcriptional activity in osteoblasts.
Increased expression of Runx2 in TIEG1 KO osteoblasts
partially rescues their mineralization defects
This laboratory has previously shown that calvarial osteoblasts
isolated from TIEG1 KO mice exhibit significant delays in
differentiation and a reduced ability to mineralize matrix [11].
This defect is associated with decreased expression of multiple
bone related genes [11]. Based on the present study in which we
have demonstrated that TIEG1 directly regulates both the
expression and activity of Runx2, it was of interest to determine
if increased Runx2 levels could rescue the mineralization defects
observed in TIEG1 KO calvarial osteoblasts. Three WT and three
TIEG1 KO cell lines were infected with either a control or Runx2
adenovirus and differentiation assays were performed over the
course of 21 days. As shown in Figure 9A, Runx2 expression levels
were significantly increased in WT and KO cells following
infection with a Runx2 adenovirus relative to control adenovirus.
Runx2 expression was increased in KO cells to levels comparable
to that of endogenous Runx2 expression in WT cells (Figure 9A).
Increased expression of Runx2 in WT cells had no effect on their
mineralization capacity (Figure 9B) suggesting that the TIEG1/
Runx2 axis was functioning maximally in these cells. However,
restoration of Runx2 expression in TIEG1 KO cells partially
rescued their mineralization defect (Figure 9B). These data suggest
that decreased expression of Runx2 in TIEG1 KO cells is at least
in part responsible for their reduced mineralization capacity and
imply an important role for Runx2 in the observed osteopenic
phenotype previously described in these mice [17,18]. However,
other important osteoblast related genes and/or pathways are
likely implicated in this defect since restoration of Runx2
expression in TIEG1 KO cells did not completely restore their
mineralization capacity to that of WT osteoblasts.
Discussion
This study demonstrates that suppression of TIEG1 results in
decreased expression of Runx2 while over-expression of TIEG1
up-regulates Runx2 levels. Runx2 promoter luciferase reporter
constructs and ChIP analyses have revealed that TIEG1’s
regulation of Runx2 expression occurs in a DNA binding
dependent manner through regulatory elements located in the
proximal region of the P1 promoter. We have also provided
Figure 6. Stabilization of TIEG1 protein levels result in
enhancement of Runx2 promoter activity. (A) Western blot
analysis depicting wild-type TIEG1 and TIEG1-NxN protein levels
following co-transfection with increasing amounts of a SIAH1 expres-
sion construct in U2OS cells using a Flag-specific primary antibody. (B)
Indicated TIEG1 expression vectors and the full-length Runx2 promoter
(2600) reporter construct were transiently transfected into U2OS cells.
Twenty four hours post-transfection, luciferase activity was monitored
and values are reported as relative fold change compared to controls.
Asterisks denote significance at the p,0.05 level (ANOVA) compared
with control values. d denotes significance at the p,0.05 level (ANOVA)
between wild-type and NxN TIEG1 expression constructs.
doi:10.1371/journal.pone.0019429.g006
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and magnitude of Runx2 expression following TGFb1 and BMP2
treatment and have implicated the ubiquitin/proteasome pathway
as another mechanism to precisely control Runx2 levels by
targeting TIEG1 for degradation. Furthermore, we have shown
that TIEG1 can interact with the Runx2 protein and serve as a co-
activator for Runx2 transcriptional activity. Finally, osteoblast
differentiation studies have demonstrated that restoration of
Runx2 expression in TIEG1 KO cells partially rescues their
mineralization defect implicating a role for this signaling pathway
in mediating the osteopenic phenotype of TIEG1 KO mice
[17,18]. Therefore, a model has evolved whereby TIEG1 serves as
an important mediator of both Runx2 expression levels and
Runx2 transcriptional activity in osteoblasts (Figure 10).
The importance of Runx2 with regard to skeletal development
and osteoblast differentiation has been well described. Runx2 plays
a critical role as a lineage determining transcription factor which is
expressed in mesenchymal precursor cells and functions to direct
their differentiation into osteoblasts [49]. Runx2 is also considered
a master regulator of osteoblast differentiation as it induces the
expression of osterix, another transcription factor whose expres-
sion is essential for terminal osteoblast differentiation and
Figure 7. TIEG1 associates with the Runx2 promoter in a DNA binding dependent manner. (A–D) Transient chromatin immunop-
recipitation (ChIP) assays were performed in U2OS cells transfected with indicated Flag-tagged expression vectors and promoter constructs for
24 hours. Chromatin was prepared, immunoprecipitated with a Flag specific antibody and amplified by both real-time PCR (A and C) and semi-
quantitative PCR (B and D). Real-time PCR analysis was utilized for quantitation purposes and the data are expressed as the abundance of the Runx2
promoter relative to cells transfected with a control expression construct. All data were normalized using input samples. Asterisks denote significance
at the p,0.05 level (ANOVA) compared with controls. d denotes significance at the p,0.05 level (ANOVA) between indicated promoter constructs.
The products obtained by semi-quantitative PCR were separated using agarose gel electrophoresis.
doi:10.1371/journal.pone.0019429.g007
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other osteoblast related genes [27,30]. Deletion of Runx2 in mice
causes arrest of osteoblast differentiation and results in neonates
with a completely cartilaginous skeleton which die shortly after
birth [34,27,30]. Furthermore, germline mutations in the Runx2
gene are strongly associated with patients diagnosed with
cleidocranial dysplasia, an autosomal dominant skeletal disorder
[51].
The precise regulation of Runx2 expression and activity is
essential for normal bone formation as mice over-expressing
Figure 8. TIEG1 interacts with and co-activates Runx2 transcriptional activity in osteoblasts. (A) U2OS cells were co-transfected with
TIEG1 and Runx2 expression constructs. Cells were lysed and equal amounts of protein were immunoprecipitated with either a Runx2 or TIEG1
specific antibody as well as an IgG control antibody. Immunoprecipitated protein complexes were separated by SDS-PAGE and western blotting was
performed using either a TIEG1 or Runx2 specific antibody. Whole cell extracts (WCE) were loaded as positive controls. Arrows indicate TIEG1 and
Runx2 protein following immunoprecipitation. (B) Representative confocal microscopy image depicting co-localization of TIEG1 and Runx2 protein in
wild-type (WT), but not TIEG1 knockout (KO), calvarial osteoblasts. (C) U2OS cells were transiently transfected with a p6OSE2 luciferase reporter
construct and TIEG1 or Runx2 expression vectors as indicated. Twenty four hours post-transfection, luciferase activity was monitored and values are
reported as relative fold change compared to empty vector controls. Asterisks denote significance at the p,0.05 level (ANOVA) compared with
control values. d denotes significance at the p,0.05 level (ANOVA) between cells transfected with Runx2 alone and cells transfected with both Runx2
and TIEG1.
doi:10.1371/journal.pone.0019429.g008
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exhibit an osteopenic phenotype [43,40]. Indeed, Runx2 has been
shown to be regulated at the level of transcriptional control,
protein activity and protein turnover. However, the specific factors
and their associated signaling pathways involved in these processes
continue to be elucidated. At the level of transcriptional control, a
small number of transcription factors have been indentified which
directly regulate Runx2 expression levels. Positive regulators of
Runx2 expression in osteoblasts include the homeobox genes,
Msx2 [52] and Bapx1 [53], as well as RBP1 [54], SP1 and ELK1
[55]. In contrast, Hoax2 [56] and Sox8 [57] have been shown to
inhibit Runx2 expression. In the present study, TIEG1 is shown to
act as a positive regulator of Runx2 expression in osteoblasts
implying an additional role for this transcription factor in
regulating osteoblastogenesis and bone development through the
actions of Runx2.
At the level of Runx2 function, many proteins have been
identified that interact with this important transcription factor to
modulate its activity. Proteins such as Stat1 [58], Sox9 [59], Aj18
[60], MEF [61], Nrf2 [62], YAP [63], HDAC4 [64], and p53 [65]
have all been shown to interact with the Runx2 protein to inhibit
its transcriptional activity. Positive regulators of Runx2 transcrip-
tional activity include CBFb1 [66–68], Smads 1 and 5 [32,69],
Satb2 [56], Rb [70], TAZ [71], HOXA10 [72], BAPX-1 [53],
RBP1 [54], C/EBPb, C/EBPd and Menin [73], among others.
This manuscript demonstrates that TIEG1 also interacts with the
Runx2 protein in osteoblast cells and serves as a co-activator of
Runx2 transcriptional activity.
In addition to individual genes and proteins affecting Runx2
expression and activity, a number of cytokines have been shown to
influence Runx2 mRNA levels. Specifically, TGFb1 and BMP2
treatment of osteoblast cells results in the rapid up-regulation or
Runx2 expression [32]. Because TIEG1 was originally identified
as a primary response gene following TGFb1 treatment [1], and
was later shown to be induced by BMP2 [3], we speculated that it
may play a role in mediating Runx2 expression by these two
factors. Indeed, Runx2 responsiveness to TGFb1 and BMP2 is
suppressed in osteoblasts isolated from TIEG1 KO mice.
Furthermore, TGFb1 and BMP2 do not lead to up-regulation of
Runx2 expression in WT cells transfected with a TIEG1 specific
siRNA. These data suggest that TIEG1 functions upstream of
Runx2 in the cascade of events that are initiated by TGFb1 and
BMP2 and implicate a role for TIEG1 in the optimal and
immediate responsiveness of Runx2 to these cytokines in bone
cells.
A final level controlling Runx2 function in osteoblasts is through
the targeted degradation of Runx2 protein. Shn3 is a zinc finger
containing adapter protein that links Runx2 with the E3 ubiquitin
ligase, WWP1 [74]. This interaction ultimately results in poly-
ubiquitination of Runx2 followed by proteasomal degradation.
Notably, TIEG1 is also highly targeted by another E3 ubiquitin
ligase family member, SIAH1 [46]. Here, we have demonstrated
that inhibiting the interaction between SIAH1 and TIEG1 results
in further activation of the Runx2 promoter. Since we have also
shown that TIEG1 and Runx2 proteins interact, one could
speculate that complexes consisting of these two proteins could be
rapidly targeted, together or separately, for proteasomal degrada-
tion. Regardless, these data further implicate the ubiquitin/
proteasome system in the regulation of Runx2 levels both through
directly targeting Runx2 protein for degradation, and by targeting
TIEG1, an inducer of Runx2 expression, for degradation. This
cellular process further serves to tightly regulate the molecular
actions of these two important bone related transcription factors.
The studies presented in this manuscript identify TIEG1 as a
novel and important regulator of Runx2 expression and activity.
TIEG1 serves as both an inducer of Runx2 expression, as well as a
co-activator of Runx2 transcriptional activity. TIEG1 is also
shown to play an important role in mediating Runx2 responses to
cytokines in osteoblast cells. The ubiquitin/proteasome system has
been implicated as another mechanism to control the levels of
Runx2 by regulating TIEG1 protein stability. Finally, a partial
Figure 9. Restoration of Runx2 expression in TIEG1 KO
osteoblasts partially rescues their differentiation and mineral-
ization defects. (A) Calvarial osteoblasts isolated from three wild-type
(WT) and three TIEG1 knockout (KO) neonatal pups were infected with
either a control or Runx2 adenovirus for 24 hours. Total RNA was
isolated and Runx2 expression levels were determined using real-time
PCR. The results are expressed as relative fold change compared to
control adenoviral infected cells and represent average Runx2
expression across three distinct cell lines. Asterisks denote significance
at the p,0.05 level (ANOVA) compared with WT control. (B) Three WT
and three TIEG1 KO calvarial osteoblast cell lines were plated in 6-well
plates and allowed to proliferate to confluence. Once confluent, cells
were cultured in osteoblastic differentiation medium in the presence of
a control or Runx2 adenovirus as indicated for 21 days. Following
differentiation, cells were stained with alizarin red and a representative
wild-type and TIEG1 KO cell line is shown.
doi:10.1371/journal.pone.0019429.g009
TIEG1 Regulation of Runx2 Expression and Activity
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e19429role for Runx2 has been identified in mediating the defects in
osteoblast differentiation and mineralization observed in TIEG1
KO mice. These observations add another dimension to the
tightly controlled and critical regulation of Runx2 expression and
function in osteoblasts and identify TIEG1 as a potential target for
approaches to treat bone related diseases resulting from defects in
any number of the cellular pathways presented here.
Materials and Methods
Cell Culture and Calvarial Osteoblast Isolation
Calvarial osteoblasts were isolated from 3 day old WT or
TIEG1 KO neonatal pups obtained from heterozygous breeding
pairs as described previously [11]. Following isolation, cells were
maintained in a-MEM (Invitrogen, Carlsbad, CA) containing 10%
(v/v) fetal bovine serum (FBS) (ISC Bioexpress, Kaysville, UT) and
1% (v/v) antibiotic/antimycotic (Invitrogen, Carlsbad, CA) in a
humidified 37uC incubator with 5% CO2. All experiments
involving calvarial osteoblasts were conducted within the first
two passages from the time of isolation. This study was carried out
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health. The protocol was approved by the Mayo Clinic
Institutional Animal Care and Use Committee (Permit Number:
A9709).
Parental U2OS cells were purchased from ATCC. The U2OS-
TIEG1 doxycycline inducible cell line (U2OS Tet-TIEG1) was
developed using parental U2OS cells and the T-Rex system
(Invitrogen) according to the manufacturer’s protocol. Cells were
cultured in phenol red-free Dulbecco’s modified Eagle’s medi-
um/F12 medium (DMEM/F12) containing 10% (v/v) FBS, 1%
(v/v) antibiotic/antimycotic, 5 mg/liter blasticidin S (Roche
Applied Science, Indianapolis, IN), and 500 mg/liter zeocin
(Invitrogen). Parental U2OS cells were cultured in DMEM/F12
containing 10% (v/v) FBS and 1% (v/v) antibiotic/antimycotic
solution.
RNA Isolation and Real-Time PCR Analysis
Wildtype and TIEG1 KO calvarial osteoblasts were plated in 12
well plates at a density of approximately 50%. To account for
individual variability of these primary cell lines, all studies were
performed in triplicate using osteoblasts isolated from three
different WT and TIEG1 KO pups. Cells were allowed to
proliferate until they were approximately 80% confluent at which
time they were washed twice with 1x PBS. Total RNA was isolated
using Trizol reagent (Invitrogen) as specified by the manufacturer.
RNA yield was determined using a NanoDrop 1000 spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE).
Five hundred ng of total RNA was reverse transcribed using
the iScript
TM cDNA Synthesis Kit (Bio-Rad, Hercules, CA).
Real-time PCR was performed in triplicate using a Bio-Rad
iCycler and a PerfeCTa
TM SYBR Green Fast Mix
TM for iQ real-
time PCR kit (Quanta Biosciences, Gaithersburg, MD) as
specified by the manufacturer. Cycling conditions were as
follows: 95uC for 2 minutes followed by 40 cycles of 95uC for 1
second and 60uC for 30 seconds. Melt curves were generated to
ensure amplification of a single PCR product. Quantitation of the
PCR results were calculated based on the threshold cycle (Ct) and
were normalized using b-tubulin for all mouse transcripts or
TATA Binding Protein (TBP) for all human transcripts. All PCR
primers were designed using Primer3 software (http://frodo.wi.
mit.edu/primer3/) and were purchased from Integrated DNA
Technologies (Coralville, IA). Primer sequences are listed in
Table 1.
Confocal Microscopy
Localization and quantitation of TIEG1 and Runx2 protein
in WT and TIEG1 KO calvarial osteoblasts were determined
using immunoflorescence histochemistry with a Zeiss LSM 510
confocal microscope (Carl Zeiss, Jena, Germany). Briefly, cells
were fixed in 1% paraformaldehyde for 30 min and washed
twice with 1X PBS. Cells were permeabilized with 0.2% Triton-
Xi nP B Sf o r3 0m i na n db l o c k e df o ra na d d i t i o n a l3 0m i ni n
heat-inactivated 5% FBS. Subsequently, cells were incubated
with a polyclonal TIEG1 antibody produced by our laboratory
(PAb # 992) and a monoclonal Runx2 antibody (clone # 8G5,
Medical and Biological Laboratories, Naka-ku Nagoya, Japan)
for 60 min. Cells were washed twice with PBS and stained with
Texas Red- and FITC-conjugated secondary IgG Antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) for an additional
60 minutes. DAPI was used as a counter stain. Relative TIEG1
and Runx2 protein levels were quantified using Zeiss LSM 510
software.
TIEG1 Specific siRNAs
Wildtype calvarial osteoblasts were cultured as above and
transfected with either a TIEG1 specific siRNA (AAUGGAA-
Figure 10. Model depicting the mechanisms by which TIEG1 mediates Runx2 expression and activity in osteoblasts.
doi:10.1371/journal.pone.0019429.g010
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sense) or a GAPDH specific siRNA. TIEG1 and non-sense
siRNAs were custom designed and purchased from Darmacon
(Lafayette, CO) while GAPDH specific siRNA was purchased
from Ambion (Austin, TX). Transient transfections were
performed using HiPerfect transfection reagent (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. Forty
eight hours post-transfection, total RNA was isolated and
reverse transcribed. TIEG1, and Runx2 expression levels were
determined via real-time PCR in each of the transfected cultures
relative to non-transfected control cells. Osteocalcin, osteopon-
tin, osterix and bone sialoprotein expression levels were
quantitated in WT calvarial osteoblasts transfected with the
TIEG1 specific siRNA relative to cells transfected with the
scrambled siRNA.
TIEG1 Over-Expression in U2OS Osteosarcoma Cells
U2OS Tet-TIEG1 cells were plated at a density of approxi-
mately 50% in triplicate in 12 well tissue culture plates. The
following day, cells were treated with 100 ng/mL of doxycycline
for 0, 8, 12 or 24 hours. Total RNA was isolated using Trizol and
reverse transcribed as specified above. TIEG1 and Runx2
expression levels were monitored via real-time PCR.
TIEG1 and Runx2 Adenovirus
The mouse TIEG1 coding sequence was cloned into the
adenoviral-Type 5 (dE1/E3) vector and adenoviral production,
amplification, purification and titer determination was conducted
by Vector Biolabs (Philadelphia, PA). A control adenovirus
containing an empty expression vector was also supplied by
Vector Biolabs. The Runx2 adenovirus was provided by Dr. Gary
Stein’s laboratory. For TIEG1 overexpression, 50% confluent
TIEG1 KO calvarial osteoblasts were infected at a multiplicity of
infection (MOI) of 10 for 24 hours. Subsequently, the expression
levels of TIEG1, Runx2, osteocalcin, osteopontin, osterix and
bone sialoprotein were determined via real-time PCR. For Runx2
overexpression in differentiating calvarial osteoblasts, confluent
WT and TIEG1 KO cells were infected at a MOI of 10 in
osteoblast differentiation medium (MEMa +10% FBS +1%
antibiotic-antimycotic +50 mg/L ascorbic acid +10 mM b-
glycerophosphate). Differentiation medium was changed every 3
days and fresh adenovirus was added with each feeding over the
course of 21 days at which time cells were fixed and stained with
alizarin red.
TGFb1 and BMP2 Treatments
Wildtype and TIEG1 KO calvarial osteoblasts were plated in
triplicate in 12 well tissue culture plates at a density of
approximately 50%. The following day, cells were treated with
vehicle (0.25% BSA in 1X PBS), TGFb1 (2 ng/mL) or BMP2
(200 ng/mL) for 2 hours. TGFb1 was purchased from Austral
Biologicals (San Ramon, CA) while BMP2 was purchased from
R&D Systems (Minneapolis, MN). Total RNA was harvested,
cDNA was prepared and real-time PCR was conducted to
determine Runx2 expression levels as described above. Addition-
ally, WT and KO calvarial osteoblasts were plated as above and
subsequently transfected with a scrambled or TIEG1 specific
siRNA, or infected with a control or TIEG1 adenovirus, for
24 hours respectively. Cells were then exposed to vehicle, TGFb1
or BMP2 for 2 hours prior to analyzing Runx2 expression levels
via real-time PCR.
Expression Vectors and Reporter Constructs
Flag-tagged full length TIEG1 (1–480 aa) or truncated TIEG1
(1–370 aa) expression constructs were developed in our laboratory
and cloned into the pcDNA4/TO expression vector (Invitrogen).
The TIEG1 1–370 construct represents deletion of the DNA
binding domain. The SIAH1 expression construct was also
developed in our laboratory and cloned into pcDNA4/TO as
previously described [46]. The flag-tagged TIEG1-NxN expres-
sion construct was kindly provided by Dr. Colin House and was
developed as previously described [47]. The TIEG1-NxN
construct contains two point mutations (V205B and P207B) which
block SIAH1 interaction and result in accumulation of TIEG1
protein levels. The Runx2 promoter constructs and expression
constructs were provided by Dr. Gary Stein’s laboratory with the
exception of the 2600 to 2101 bp construct which was cloned in
our laboratory. All promoter constructs were ligated into the
pGL3-basic luciferase vector (Promega, Madison, WI). The
transcription factor binding site search using the 2600 bp
fragment of the Runx2 promoter as a template was performed
using the Genomatix software suite (Munich, Germany). The
p6OSE2-Luc reporter construct was originally developed by Dr.
Patricia Ducy [48].
Table 1. Primer sets used in qRT-PCR and ChIP assays.
Primer, 59 -3 9
Gene Forward Reverse
mRunx2 GCCGGGAATGATGAGAACTA GGTGAAACTCTTGCCTCGTC
mOsteocalcin GCCATCACCCTGTCTCCTAA GCTGTGGAGAAGACACACGA
mOsteopontin CCCGGTGAAAGTGACTGATTCT GATCTGGGTGCAGGCTGTAAA
mOsterix GGAGGTTTCACTCCATTCCA TAGAAGGAGCAAGGGGACAGA
mBone Sialoprotein TTCCCAGGTGTGTCATTGAAGA GGTATGTTTGCGCAGTTAGCAA
mKLF10 GTGACCGTCGGTTTATGAGG ACTTCCATTTGCCAGTTTGG
hRunx2 CCAGATGGGACTGTGGTTACTG TTCCGGAGCTCAGCAGAATAA
hKLF10 GCCAACCATGCTCAACTTCG TGCAGTTTTGTTCCAGGAATACAT
mb-Tubulin CTGCTCATCAGCAAGATCAGAG GCATTATAGGGCTCCACCACAG
hTBP AGTTGTACAGAAGTTGGGTTTTC AACAATTCTGGGTTTGATCATTC
Runx2 ChIP AATAGTGCTTGCAAAAAATAGGAGTTT TGGCGTCTTCCATGGTGGCTTTAC
doi:10.1371/journal.pone.0019429.t001
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U2OS cells were plated in 12 well plates at a density of
approximately 50%. The following day, cells were transfected in
triplicate with 250 ng of either full length (1–480 aa) or truncated
(1–370 aa) TIEG1 expression constructs and 250 ng of indicated
reporter constructs using Fugene 6 (Roche, Indianapolis, IN) as
described by the manufacturer. Following incubation at 37uC for
24 hours, cells were washed twice with PBS, lysed in 1X Passive
Lysis Buffer (Promega) and equal quantities of protein extract were
assayed for luciferase activity using Luciferase Assay Reagent
(Promega).
Western Blotting
To determine TIEG1 and TIEG1-NxN protein levels following
co-transfection with SIAH1 in U2OS cells, whole cell extracts
were prepared. Equal amounts of extract were separated using
SDS PAGE, transferred to PVDF and blocked overnight in 5%
milk in 1X TBST. Membranes were probed with a monoclonal
Flag antibody (M2, Sigma, St. Louis, MO) and TIEG1 protein
levels were visualized using enhanced chemiluminescence (Amer-
sham Biosciences, Piscataway, NJ).
Chromatin Immunoprecipitation (ChIP) Assays
U2OS cells were plated at a density of approximately 50% in
100 mm tissue culture plates and transfected in triplicate with 5 mg
of both the indicated reporter and expression constructs as
specified above. Following incubation for 24 hours, ChIP assays
were performed as previously described [2]. Immunoprecipitations
were carried out using 0.5 mg of a M2-Flag specific monoclonal
antibody (Sigma). Inputs were generated as above excluding the
antibody immunoprecipitation. Semi-quantitative PCR and quan-
titative Real-Time PCR were conducted in triplicate on all
samples and a representative data set is shown. Primers used in the
PCR reactions were designed to amplify the Runx2 promoter and
are listed in Table 1. Quantitative PCR values were calculated
based on the threshold cycle (Ct) and were normalized to input
controls.
Co-Immunoprecipitation Assays
U2OS cells were plated at a density of approximately 50% in
100 mm tissue culture plates and transfected as indicated with
5 mg of TIEG1 or Runx2 expression constructs. Following
24 hours of incubation, cells were washed twice with PBS and
lysed in RIPA buffer. Equal amounts of cell lysates were
immunoprecipitated at 4uC overnight using 1 mg of either rabbit
IgG, a Runx2 M-70 specific antibody (Santa Cruz) or a TIEG1
specific polyclonal antibody (#992-generated in our laboratory).
Protein complexes were purified using protein G beads. Com-
plexes were separated by SDS-PAGE, transferred to PVDF and
blocked in 5% milk overnight. Western blotting was performed
using either a TIEG1 specific polyclonal antibody (#992) or a
Runx2 M-70 specific antibody (Santa Cruz).
Differentiation of Calvarial Osteoblasts
Wildtype and TIEG1 KO calvarial osteoblasts were plated in 6-
well tissue culture plates and allowed to proliferate to confluence.
Once confluent, cells were cultured in osteoblastic differentiation
medium containing b-glycerophosphate and ascorbic acid in the
presence of either a control or Runx2 adenovirus as described
above. Differentiation medium was replaced every three days.
Following 21 days of differentiation, cells were stained for calcified
bone nodules using Alizarin Red (Sigma-Aldrich). Briefly, cells
were washed in 1X PBS and fixed in 10% neutral buffered
formalin overnight at room temperature. Cells were washed twice
with PBS and stained with 2% Alizarin Red (v/v) ph 4.2 for 10
minutes. Cells were washed extensively with distilled water and
subsequently scanned.
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